Remote Ischemic Preconditioning in the PICU: A Simple Concept With a Complex Past

Dana Y Fuhrman1, John A Kellum

  • 1All authors: Department of Critical Care Medicine, University of Pittsburgh, School of Medicine, Pittsburgh, PA.

Insights

Remote ischemic preconditioning shows promise for organ protection but faces challenges in pediatric critical care. Further research and standardized protocols are needed for its clinical application in children.

Area of Science:

  • Cardiology
  • Critical Care Medicine
  • Physiology

Background:

  • Remote ischemic preconditioning (RIPC) is a protective phenomenon where brief ischemia in one organ confers resistance to a distant organ against subsequent ischemic injury.
  • Despite over two decades of research, RIPC is not routinely used in pediatric critical care, necessitating a review of its mechanisms, clinical applications, and barriers to adoption.

Purpose of the Study:

  • To review recent mechanisms of RIPC.
  • To summarize clinical studies on RIPC over the past decade, focusing on pediatric critical care.
  • To identify reasons for the limited clinical use of RIPC in pediatric patients and discuss future research directions.

Main Methods:

  • A systematic literature search was conducted using PubMed with terms 'ischemic preconditioning' and 'remote preconditioning'.
  • Included were randomized controlled trials from 2006 to the present that utilized a blood pressure cuff for RIPC induction.
  • Reference lists of identified articles were reviewed, and all studies involving pediatric patients were included.

Main Results:

  • Varied study outcomes regarding RIPC's organ-protective effects have been reported, potentially hindering clinical translation.
  • The lack of standardized protocols and clearly defined patient risk groups may contribute to inconsistent findings.

Conclusions:

  • Differences in study outcomes and methodology have limited the routine clinical application of RIPC in pediatric critical care.
  • Future research should focus on protocolizing RIPC in large multicenter trials, utilizing biomarkers, and clearly delineating patient risk groups to establish safety and efficacy in critically ill children.
Abstract